Xenon Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell XENE and other ETFs, options, and stocks.

About XENE

Xenon Pharmaceuticals, Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. 

CEO
Ian C. Mortimer
CEOIan C. Mortimer
Employees
370
Employees370
Headquarters
Burnaby, British Columbia
HeadquartersBurnaby, British Columbia
Founded
1996
Founded1996
Employees
370
Employees370

XENE Key Statistics

Market cap
6.33B
Market cap6.33B
Price-Earnings ratio
-13.54
Price-Earnings ratio-13.54
Dividend yield
Dividend yield
Average volume
593.02K
Average volume593.02K
High today
$64.36
High today$64.36
Low today
$62.86
Low today$62.86
Open price
$62.98
Open price$62.98
Volume
510.22K
Volume510.22K
52 Week high
$72.66
52 Week high$72.66
52 Week low
$32.78
52 Week low$32.78

Stock Snapshot

The current Xenon Pharmaceuticals(XENE) stock price is $64.30, with a market capitalization of 6.33B. The stock trades at a price-to-earnings (P/E) ratio of -13.54.

On 2026-08-11, Xenon Pharmaceuticals(XENE) stock moved within a range of $62.86 to $64.36. With shares now at $64.30, the stock is trading +2.3% above its intraday low and -0.1% below the session's peak.

Trading activity shows a volume of 510.22K, compared to an average daily volume of 593.02K.

The stock's 52-week range extends from a low of $32.78 to a high of $72.66.

The stock's 52-week range extends from a low of $32.78 to a high of $72.66.

XENE News

Simply Wall St 3d
FDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc. has reported past second-quarter 2026 results showing a net loss of US$110.74 million and basic and diluted loss per share of US$1.11...

FDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals

Analyst ratings

100%

of 18 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own XENE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.